Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
about
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumabEpithelial membrane protein-1 is a biomarker of gefitinib resistance.Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateChallenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategiesWill kinase inhibitors make it as glioblastoma drugs?In vitro and in vivo models for analysis of resistance to anticancer molecular therapiesThe epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredMolecular pathology of lung cancer: key to personalized medicine.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cellsAntitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsCellular effects of HER3-specific affibody moleculesRestoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.EGFR associated expression profiles vary with breast tumor subtypePharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancerEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesAn ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationThe phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradationMultiple roles and therapeutic implications of Akt signaling in cancer.Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesProtein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA studyThe phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Notch-EGFR/HER2 Bidirectional Crosstalk in Breast CancerTargeting the function of the HER2 oncogene in human cancer therapeutics.Metformin and erlotinib synergize to inhibit basal breast cancer.MicroRNA gene dosage alterations and drug response in lung cancerAd-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
P2860
Q24313194-3F837C41-FF16-4690-9E74-2E82D638DF80Q24535592-878DB912-4680-47E9-BDCF-C8FF46F42602Q24633878-E5201CE3-6CC0-4096-BAE0-1CC0B6FF376AQ24810622-C4A85A2D-B390-4C81-B874-DDC92226C040Q26822717-71CFCA79-6300-4499-A896-F19F86D91406Q26852366-D670CB44-62E6-47CF-981A-E5581A3B9958Q27012684-4F81F2FC-AA52-4F98-87AA-D863A89D9A46Q27014174-EC43822E-5DA2-42AB-BF00-93BB0A1488C3Q27015045-A74F26EF-97C0-4C17-ACE8-385FA14C8B1CQ27691299-3532BB4E-CF7C-4471-9978-6B810C41F849Q27851396-EA884120-5F95-4213-A1C9-B7F5A335EBF0Q27852452-AD9DA95E-3EEA-40DC-B648-4BB8B21FAB55Q28472048-85973BC3-F34D-4F32-AF79-5C9F2554C65BQ28478344-ADF41FA8-FD97-4210-9CF5-5A389EBEC80DQ28727774-BAC5478C-BDE4-44CB-93E2-8DCA294AE3BFQ30438487-F6E5D959-E9EC-4527-B3CB-27D0712E48B7Q33292502-61818322-C6D4-4F20-94C4-C80E98D01C74Q33397545-08A1D576-5302-4CBA-B8F8-E2A7F7E4B65FQ33529070-F40C4CEE-34EC-489A-9F2D-7130281A0107Q33608491-7E6A3980-D4BE-44B5-BD70-93DBC6CEC0CBQ33691211-2FB19DFF-BA56-4069-A895-2C6F63C1A6F1Q33733313-123C384E-8174-44D1-AB22-E6CF3B952A9AQ33778905-184D67D3-4FA5-49A8-9469-21F5E4C48FD4Q33915992-B45138D4-7A0D-4940-960D-6DB4C2F90BCDQ33924908-F5D602FE-ADCD-4DBF-BAE0-4DD86F3E7AF8Q33928631-32BC8C2D-49D9-4421-B7DD-4F08811A3ACFQ34067863-94B20F51-410E-433D-968F-1D47DBE1E081Q34088424-041C561C-810F-47B6-B51B-FD314F828BD9Q34093266-4225C7C2-257A-4D8F-968D-D07B1132B666Q34132872-5913A4EB-1BA6-4A4C-A7C7-93BFD6F5C1FFQ34485373-72D3C4D4-CA4C-4E84-93F3-36D88B9C2888Q34524510-40379271-BAD8-4B34-8614-A92AC012E705Q34557318-53463160-D3FF-4194-AEA5-B6AE84AB9F2CQ34686900-BEAFCA3D-3C0F-45DF-8E64-E490BFE79437Q34766486-F5503FC9-C16D-4BCF-AC00-69D20D04B06CQ34786488-CEE06416-D1C6-4FCC-9D89-90168A242DE4Q34897598-84FF9A97-D17B-4168-ADCA-53E1BCA0ADA5Q35012485-B3D64C04-BA7E-4055-A94F-9FFE830CA28EQ35469548-8ABD0B40-8172-4F33-BC2D-67B8FF2EA1BFQ35566234-0DD333DF-A3DB-4A6A-874C-913C9606C6F0
P2860
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@en
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@nl
type
label
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@en
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@nl
prefLabel
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@en
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@nl
P2093
P2860
P356
P1433
P1476
Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.
@en
P2093
Andrea Basso
Carlos L Arteaga
Christoph A Ritter
F Michael Yakes
Gordon B Mills
Incheol Shin
Junji Tsurutani
Neal Rosen
Phillip A Dennis
Roberto Bianco
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206388
P407
P577
2003-05-01T00:00:00Z
P5875
P6179
1004564925